Question

In: Accounting

Colonial Pharmaceuticals is a start-up small firm specializing in new medications. It is organized into two...

Colonial Pharmaceuticals is a start-up small firm specializing in new medications. It is organized into two divisions, which are based on the products they produce. AC Division is smaller and the life of the products it produces tend to be shorter than those produced by the larger SO Division. Selected financial data for the past year is shown below. Colonial Pharmaceuticals uses a 9 percent cost of capital for divisional performance analysis.

Business Unit

AC Division

SO Division

Sales revenue

$8,000,000

$20,000,000

After-tax operating profit

$1,200,000

$4,800,000

R&D expenditures

$2,000,000

$3,600,000

Divisional assets

$9,000,000

$80,000,000

Divisional current liabilities

$800,000

$4,000,000

R&D is assumed to have a two-year life in the AC Division and a nine-year life in the SO division. All R&D expenditures are spent at the beginning of the year. Since Colonial is a start-up, we can assume that no R&D expenditures had taken place before this year.

Required

  1. Calculate ROI (using the DuPont formula) for the two divisions.
  2. Compute residual income for the two divisions.
  3. Compute EVA for the two divisions.
  4. Briefly assess the financial performance of the two divisions based on your analysis.

Solutions

Expert Solution

A. ROI = Profit/Invested capital

Division AC Division SO
A Profit 1200000 4800000
B Invested capital [Asset - Current liabilities] 8200000 7600000
ROI [A/B] 14.63% 63.16%

B. Residual income = Operating income - [Total assets*Target rate of return]

Division AC Division SO
A Operating income 1200000 4800000
B Minimum required rate of return 0.09 0.09
C Operating assets 9000000 8000000
D Required return [B*C] 810000 720000
E Residual income [A-D] 390000 4080000

C. EVA = Net Operating Profit After Taxes (NOPAT) - Invested Capital * Weighted Average Cost of Capital (WACC)

Division AC Division SO
A NOPAT 1200000 4800000
B Unamorised research expenditure 1000000 3200000
[2000000/2] [3600000/9 * 8]
C NOPAT for EVA [ A+B] 2200000 8000000
D Invested capital [Asset - Current liabilities] 8200000 7600000
E WACC 9% 9%
EVA 1462000 7316000

d. Division SO has performed better than AC division on all fronts.

It has a high ROI of 63.16% while division AC has a ROI of 14.63%.

Similarly, it has a very high residual income and EVA in contrast to that of division AC.

If you found the above answer useful, then request you to please take a moment to up-vote the same. It will help me to keep serving you better!



Related Solutions

Colonial Pharmaceuticals is a small firm specializing in new products. It is organized into two divisions,...
Colonial Pharmaceuticals is a small firm specializing in new products. It is organized into two divisions, which are based on the products they produce. AC Division is smaller and the life of the products it produces tend to be shorter than those produced by the larger SO Division. Selected financial data for the past year is shown as follows. Divisional investment is as of the beginning of the year. Colonial Pharmaceuticals uses a 9 percent cost of capital and uses...
Colonial Pharmaceuticals is a small firm specializing in new products. It is organized into two divisions,...
Colonial Pharmaceuticals is a small firm specializing in new products. It is organized into two divisions, which are based on the products they produce. AC Division is smaller and the life of the products it produces tend to be shorter than those produced by the larger SO Division. Selected financial data for the past year is shown below. Divisional investment is as of the beginning of the year. Colonial Pharmaceuticals uses a 9 percent cost of capital and uses beginning-of-the-year...
You have a new start-up firm. You think that the value of your start-up is around...
You have a new start-up firm. You think that the value of your start-up is around $60 million, but you will need to do a serious NPV analysis before you know the precise value. You are planning to have a 50% debt-to-value ratio, and that you will continuously rebalance to maintain this leverage. You have information on two other companies. The names of these companies are “Comp A” and “Comp B”. Comp A has the same business risk as your...
Hansus Enterprises is a start-up small business specializing in software systems for machine-based high-school student tutoring...
Hansus Enterprises is a start-up small business specializing in software systems for machine-based high-school student tutoring in science and math. Sheryl Hansus, the owner, has spoken with lenders to obtain a loan of $50,000 now (year 0), and the same amount in years 3 and 6. Two different repayment schedules are available. They are: Schedule A: Pay a uniform amount of $19,500 in years 3 through 12. Schedule B: Pay a uniform amount of $20,000 in years 1 through 6,...
Virusator is a bio-medical start-up specializing in producingvaccines and treatments to battle dangerous viruses. To...
Virusator is a bio-medical start-up specializing in producing vaccines and treatments to battle dangerous viruses. To finance its activities it recently took a one year loan of two million dollars, at an annual effective rate of 10%. It must repay the loan in September 2021 (a year from now). Earnings this coming year are expected to be $3.3 million. Assume earning are received in September 2021 (i.e, one year from now). To finance growth it plans on reinvesting 90% of...
A start-up firm as developed a new email app that allows the user to decide what...
A start-up firm as developed a new email app that allows the user to decide what mail gets into their mail box. This company doesn't have a lot of start-up capital and they are funded by a Venture Capital firm that wants an expected 18% return. They are going to use the Agile model and release various versions of their app overtime as they see what works. There 3- year start up plan includes: Initial Development Expenses of $100,000 per...
ASP Pharmaceuticals has decided to go ahead and start clinical trials on a new drug. The...
ASP Pharmaceuticals has decided to go ahead and start clinical trials on a new drug. The total R&D costs are estimated to reach $750,000,000 with clinical trials mounting to $120,000,000. The current market size is estimated to be 2,000,000 and is expected to grow at 3% every year. The market share ASP hopes to capture in the first year is 8%, and is projected to grow by 20% each year for the next 4 years. A monthly prescription is anticipated...
You work for a venture capital firm and are approached to finance a new high-tech start-up....
You work for a venture capital firm and are approached to finance a new high-tech start-up. While you believe in the business idea, you also believe it is very risky. What strategies can help to mitigate the risk to your firm? Explain how these measures would work.
You are a manager at Das Köstliche Waffelhaus, a small food manufacturing firm specializing in the...
You are a manager at Das Köstliche Waffelhaus, a small food manufacturing firm specializing in the production of frozen waffles. The CEO of the company has asked you assess optimal profitability at one of your factories (factory A). Currently, factory A contains 3 AquaPruf series stainless steel conveyor systems for mixing and baking the waffles. These machines have an estimated monthly maintenance cost of $1500 each. Your firm also has an installed freezer system which costs $2000 per month total...
You are a manager in a start-up firm based in Bengaluru. The firm is planning to...
You are a manager in a start-up firm based in Bengaluru. The firm is planning to go public and you have been tasked at arriving at an approximate valuation for the firm. The firm is in the business of providing medical grade pure water. The asset beta of the firms’ in the industry with similar size is 1.3 and 1.4. The risk free rate is 5% and the market risk premium is 7%. At present, the firm doesn’t have any...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT